L Dalle Carbonare1, V Micheletti2, E Cosaro2, M T Valenti3, M Mottes3, G Francia4, M V Davì2. 1. Department of Medicine, Medicina Interna D, University of Verona, Piazzale Scuro, Policlinico G.B. Rossi, 37134, Verona, Italy. luca.dallecarbonare@univr.it. 2. Department of Medicine, Medicina Interna D, University of Verona, Piazzale Scuro, Policlinico G.B. Rossi, 37134, Verona, Italy. 3. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy. 4. Endocrinology Unit, Ospedale Pederzoli, Peschiera del Garda, Verona, Italy.
Abstract
CONTEXT: The high risk of vertebral fractures (VFs) in acromegaly patients despite normal bone mineral density (BMD) is well known. The reasons for this paradoxical finding of skeleton fragility are poorly understood due to the limited data on bone histomorphometry in acromegaly. OBJECTIVE: This study aimed to analyze histomorphometric parameters including bone microarchitecture in acromegaly patients with VFs and normal BMD compared to normal subjects, and also to evaluate the differences between active and controlled acromegaly patients. PATIENTS AND METHODS: Forty-seven acromegaly patients (17 active, 30 controlled), median (range) age 57 years (30-88) were evaluated for bone turnover, morphometric VFs and BMD by dual-energy X-ray absorptiometry at lumbar spine and hip; 12 patients with VFs and normal BMD underwent iliac crest bone biopsy; 12 biopsies were taken at the autopsy in healthy sex and age-matched control subjects. RESULTS: The histomorphometric evaluation of acromegaly fractured patients was compared with that of normal controls and showed significantly reduced median (range) levels of bone volume/tissue volume (BV/TV: 15.37% (7.93-26.75) vs. 18.61% (11.75-27.31), p = 0.036), trabecular thickness (TbTh: 77.6 µm (61.7-88.3) vs. 82.7 µm (72.3-92.0) p = 0.045), with increased trabecular separation (TbSp: 536.4 µm (356.2-900.6) vs. 370.3 µm (377.1-546.3) p = 0.038) and increased cortical thickness (1268 μm (752-2521) vs. 1065 μm (851-1205) p = 0.025) and porosity (11.9% (10.2-13.3) vs. 4.8% (1.6-8.8) p = 0.0008). While active acromegaly patients showed histomophometric features of increased bone turnover, patients with controlled disease presented normal bone turnover with significantly lower osteoblastic activity, expressed as osteoblast number (p = 0.001), active osteoblasts and vigor (p = 0.014) in the presence of reduced osteocyte number (p = 0.008) compared to active disease. CONCLUSIONS: The apparent paradox of bone fragility in acromegaly patients with a normal BMD can be explained by increased cortical thickness and porosity and reduced trabecular thickness with increased trabecular separation. These structural and microarchitectural abnormalities persist in the controlled phase of acromegaly despite bone turnover normalization. The main determinant of bone disease after hormonal control is severe osteoblastic dysfunction.
CONTEXT: The high risk of vertebral fractures (VFs) in acromegalypatients despite normal bone mineral density (BMD) is well known. The reasons for this paradoxical finding of skeleton fragility are poorly understood due to the limited data on bone histomorphometry in acromegaly. OBJECTIVE: This study aimed to analyze histomorphometric parameters including bone microarchitecture in acromegalypatients with VFs and normal BMD compared to normal subjects, and also to evaluate the differences between active and controlled acromegalypatients. PATIENTS AND METHODS: Forty-seven acromegalypatients (17 active, 30 controlled), median (range) age 57 years (30-88) were evaluated for bone turnover, morphometric VFs and BMD by dual-energy X-ray absorptiometry at lumbar spine and hip; 12 patients with VFs and normal BMD underwent iliac crest bone biopsy; 12 biopsies were taken at the autopsy in healthy sex and age-matched control subjects. RESULTS: The histomorphometric evaluation of acromegaly fracturedpatients was compared with that of normal controls and showed significantly reduced median (range) levels of bone volume/tissue volume (BV/TV: 15.37% (7.93-26.75) vs. 18.61% (11.75-27.31), p = 0.036), trabecular thickness (TbTh: 77.6 µm (61.7-88.3) vs. 82.7 µm (72.3-92.0) p = 0.045), with increased trabecular separation (TbSp: 536.4 µm (356.2-900.6) vs. 370.3 µm (377.1-546.3) p = 0.038) and increased cortical thickness (1268 μm (752-2521) vs. 1065 μm (851-1205) p = 0.025) and porosity (11.9% (10.2-13.3) vs. 4.8% (1.6-8.8) p = 0.0008). While active acromegalypatients showed histomophometric features of increased bone turnover, patients with controlled disease presented normal bone turnover with significantly lower osteoblastic activity, expressed as osteoblast number (p = 0.001), active osteoblasts and vigor (p = 0.014) in the presence of reduced osteocyte number (p = 0.008) compared to active disease. CONCLUSIONS: The apparent paradox of bone fragility in acromegalypatients with a normal BMD can be explained by increased cortical thickness and porosity and reduced trabecular thickness with increased trabecular separation. These structural and microarchitectural abnormalities persist in the controlled phase of acromegaly despite bone turnover normalization. The main determinant of bone disease after hormonal control is severe osteoblastic dysfunction.
Entities:
Keywords:
Acromegaly; Bone biopsy; Bone fragility; Vertebral fractures
Authors: Adnan Ajmal; Arezoo Haghshenas; Shirin Attarian; Maya Barake; Nicholas A Tritos; Anne Klibanski; Karen K Miller; Lisa B Nachtigall Journal: Pituitary Date: 2014-08 Impact factor: 4.107
Authors: T Ueland; E N Ebbesen; J S Thomsen; L Mosekilde; K Brixen; A Flyvbjerg; J Bollerslev Journal: Eur J Clin Invest Date: 2002-02 Impact factor: 4.686
Authors: Miguel Madeira; Leonardo Vieira Neto; Francisco de Paula Paranhos Neto; Inayá Corrêa Barbosa Lima; Laura Maria Carvalho de Mendonça; Mônica Roberto Gadelha; Maria Lucia Fleiuss de Farias Journal: J Clin Endocrinol Metab Date: 2013-03-12 Impact factor: 5.958
Authors: K M J A Claessen; H M Kroon; A M Pereira; N M Appelman-Dijkstra; M J Verstegen; M Kloppenburg; N A T Hamdy; N R Biermasz Journal: J Clin Endocrinol Metab Date: 2013-09-30 Impact factor: 5.958
Authors: Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli Journal: Endocrine Date: 2020-02-14 Impact factor: 3.633
Authors: Luis Gracia-Marco; Sheila Gonzalez-Salvatierra; Antonia Garcia-Martin; Esther Ubago-Guisado; Beatriz Garcia-Fontana; José Juan Gil-Cosano; Manuel Muñoz-Torres Journal: J Clin Med Date: 2021-02-09 Impact factor: 4.241
Authors: Kim M J A Claessen; Iris C M Pelsma; Herman M Kroon; Antoon H van Lierop; Alberto M Pereira; Nienke R Biermasz; Natasha M Appelman-Dijkstra Journal: Endocrine Date: 2021-08-26 Impact factor: 3.633